Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Colorectal Neoplasms 22Breast Neoplasms 22Stomach Neoplasms 21Neoplasms 18Esophageal Squamous Cell Carcinoma 12Neoplasm Metastasis 11Nasopharyngeal Carcinoma 11Lung Neoplasms 11Rectal Neoplasms 9Colonic Neoplasms 8Pancreatic Neoplasms 7Uterine Cervical Neoplasms 6Esophageal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Osteosarcoma 5Brain Neoplasms 5Small Cell Lung Carcinoma 4Recurrence 4Glioblastoma 4Gastrointestinal Neoplasms 4Precision Cell Immunotherapy 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Head and Neck Neoplasms 3Gastrointestinal Diseases 3Digestive System Neoplasms 3Carcinoma, Ovarian Epithelial 3

Interventions

Azacitidine 10Decitabine 9Cyclophosphamide 9Cytarabine 7Tacrolimus 6Antilymphocyte Serum 6fludarabine phosphate 5Mycophenolic Acid 5Melphalan 5Busulfan 5fludarabine 4Whole-Body Irradiation 4Peripheral Blood Stem Cell Transplantation 4Idarubicin 4Rituximab 3Polymerase Chain Reaction 3Lenalidomide 3Filgrastim 3venetoclax 2sargramostim 2Tretinoin 2Radiotherapy 2Methylprednisolone 2Methotrexate 2Flow Cytometry 2Etoposide 2Cyclosporine 2Cord Blood Stem Cell Transplantation 2Clofarabine 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Myelodysplastic Syndromes × Drug Therapy × Clear all
NCT04764513 2022-03-28

Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT

Chinese PLA General Hospital

Phase 1/2 Unknown
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡